Navigating advanced polycystic kidney disease: a case study of bilateral nephrectomy and life-saving transplant

Fathimath Suooda; Fathimath Maleesha; Fathmath Zuha Ali; Yulia Karpovich Ivanovna

doi:10.18203/2320-6012.ijrms20250697

Authors

Fathimath Suooda Department of Internal Medicine, Grodno State Medical University, Belarus
Fathimath Maleesha Department of Internal Medicine, Grodno State Medical University, Belarus
Fathmath Zuha Ali Department of Internal Medicine, Grodno State Medical University, Belarus
Yulia Karpovich Ivanovna Department of Internal Medicine, Grodno State Medical University, Belarus

DOI:

https://doi.org/10.18203/2320-6012.ijrms20250697

Keywords:

Polycystic kidney disease, End stage renal disease, Autosomal dominant polycystic kidney disease, Renal replacement therapy

Abstract

This case report discusses a 60-year-old female with polycystic kidney disease (PKD) who developed end-stage renal disease (ESRD). Diagnosed with polycystic kidney and liver disease in 2004, her condition worsened over the years, ultimately requiring hemodialysis and, later, kidney transplantation. Pre-transplant preparations included bilateral nephrectomy due to extensive cystic involvement of both kidneys. Post-transplant follow-up showed marked improvement in kidney function, with careful management using immunosuppressive, antifungal, and antihypertensive medications to prevent rejection and infection. This case underscores the critical role of multidisciplinary care in PKD patients undergoing transplantation for ESRD.

Metrics

Metrics Loading ...

References

Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50. DOI: https://doi.org/10.1038/s41572-018-0047-y

Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Society Nephrol. 2002;13(9):2384-98. DOI: https://doi.org/10.1097/01.ASN.0000028643.17901.42

Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest. 2014;124(6):2315-24. DOI: https://doi.org/10.1172/JCI72272

Peters DJ, Sandkuijl LA. Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol. 1992;97:128-39. DOI: https://doi.org/10.1159/000421651

Lanktree MB, Haghighi A, Di Bari I, Song X, Pei Y. Insights into autosomal dominant polycystic kidney disease from genetic studies. Clin J Am Society Nephrol. 2021;16(5):790-9. DOI: https://doi.org/10.2215/CJN.02320220

Shin MH, Choi NK. Incidental renal cell carcinoma post bilateral nephrectomy in autosomal dominant polycystic kidney disease. World J Clin Cases. 2024;12(28):6187-94. DOI: https://doi.org/10.12998/wjcc.v12.i28.6187

Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney-Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88(1):17-27. DOI: https://doi.org/10.1038/ki.2015.59

Rai V, Singh M, Holthoff JH. New Mutation Associated with Polycystic Kidney Disease Type I: A Case Report. Genes (Basel). 2024;15(10):1262. DOI: https://doi.org/10.3390/genes15101262

Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, et al. Unified Criteria for Ultrasonographic Diagnosis of ADPKD. J Am Society Nephrol. 2009;20(1):205-12. DOI: https://doi.org/10.1681/ASN.2008050507

Tsai TY, Chen CH, Wu MJ, Tsai SF. Outcomes of Kidney Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: Our Experience Based on 35-Years Follow-Up. Diagnostics. 2022;12(5):1174. DOI: https://doi.org/10.3390/diagnostics12051174

Kim Y, Han S. Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease. Kor J Intern Med. 2023;38(3):322-31. DOI: https://doi.org/10.3904/kjim.2022.376

Liebau MC, Mekahli D, Perrone R, Soyfer B, Fedeles S. Polycystic Kidney Disease Drug Development: A Conference Report. In: Kidney Medicine. Elsevier Inc. 2023. DOI: https://doi.org/10.1016/j.xkme.2022.100596

Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Caskey F, et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 2014;86(6):1244-52. DOI: https://doi.org/10.1038/ki.2014.120

Messing M, Torres JA, Holznecht N, Weimbs T. Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression. Nutrients. 2024;16(19):3281. DOI: https://doi.org/10.3390/nu16193281

Harris PC, Torres VE. Polycystic kidney disease. Ann Rev Med. 2009;60:321-37. DOI: https://doi.org/10.1146/annurev.med.60.101707.125712